196 related articles for article (PubMed ID: 35283623)
1. One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives.
Spoelstra SK; Bruins J; Bais L; Seerden P; Castelein S; Knegtering H
Patient Prefer Adherence; 2022; 16():615-624. PubMed ID: 35283623
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
3. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
4. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
Basu A; Benson C; Alphs L
J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
6. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
[TBL] [Abstract][Full Text] [Related]
7. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.
Fernández-Miranda JJ; Díaz-Fernández S; De Berardis D; López-Muñoz F
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915786
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
10. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
[TBL] [Abstract][Full Text] [Related]
11. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
12. Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
Li G; Keenan A; Daskiran M; Mathews M; Nuamah I; Orman C; Joshi K; Singh A; Godet A; Pungor K; Gopal S
Patient Prefer Adherence; 2021; 15():2239-2248. PubMed ID: 34629867
[TBL] [Abstract][Full Text] [Related]
13. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
Wallman P; Clark I; Taylor D
J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
[TBL] [Abstract][Full Text] [Related]
15. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
[TBL] [Abstract][Full Text] [Related]
16. Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.
El Khoury AC; Patel C; Mavros P; Huang A; Wang L; Bashyal R
Neuropsychiatr Dis Treat; 2021; 17():3159-3170. PubMed ID: 34703236
[TBL] [Abstract][Full Text] [Related]
17. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
[No Abstract] [Full Text] [Related]
18. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
[TBL] [Abstract][Full Text] [Related]
20. Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal.
García-Carmona JA; Pappa S
Drug Healthc Patient Saf; 2023; 15():113-123. PubMed ID: 37720806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]